Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection
The treatment of severe or persistent acute rejection remains difficult despite newer immunosuppressive agents available. To evaluate the effectiveness of rabbit antithymocyte globulin and methotrexate as therapy for severe or persistent acute cardiac allograft rejection, we conducted a retrospectiv...
Gespeichert in:
| Veröffentlicht in: | The Annals of thoracic surgery 1995-08, Vol.60 (2), p.372-376 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 376 |
|---|---|
| container_issue | 2 |
| container_start_page | 372 |
| container_title | The Annals of thoracic surgery |
| container_volume | 60 |
| creator | Ferraro, Pasquale Carrier, Michel White, Michel Pelletier, Guy B. Pelletier, L. Conrad |
| description | The treatment of severe or persistent acute rejection remains difficult despite newer immunosuppressive agents available.
To evaluate the effectiveness of rabbit antithymocyte globulin and methotrexate as therapy for severe or persistent acute cardiac allograft rejection, we conducted a retrospective analysis of clinical and laboratory data from 150 consecutive heart transplant recipients between 1983 and 1994.
Thirteen episodes of severe or refractory acute rejection were treated with rabbit antithymocyte globulin in 10 patients. Rabbit antithymocyte globulin (125 mg/day for 3 consecutive days) was effective in 90% of patients. Therapy was well tolerated, and contributed to one infectious complication, no malignancy, and long-term survival in 8 of 10 patients. Recurrent rejection developed in 60% of patients. Methotrexate (7.5 to 15 mg/wk for 16 weeks) was administered to 8 patients with persistent rejection documented on three consecutive endomyocardial biopsies. Therapy was effective in 6 of the 8 patients, with one infectious complication and no malignancy on follow-up. White blood cell count decreased significantly during therapy (
p = 0.008). Seven of the 8 patients in the methotrexate group are long-term survivors.
Rabbit antithymocyte globulin is a valuable alternative in patients with severe or refractory acute rejection. Methotrexate is an important adjunct in patients with persistent rejection unresponsive to conventional immunosuppressive regimens. |
| doi_str_mv | 10.1016/0003-4975(95)00414-G |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77458856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000349759500414G</els_id><sourcerecordid>77458856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-3aa49e711f93c7258bbb06ecee5a6e903e38878c0321e8a1031e25797799c7743</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo67j6DxRykEUPvSadr85FWBYdhQUv6zlUp6t3snR3xiSzOP9-M84wR09F8T5vUTyEvOfsmjOuvzDGRCOtUZ-s-syY5LJZvyArrlTb6FbZl2R1Rl6TNzk_1rWt8QW5MFpqZrsV8TdLCWWzn6PfF6QPU-x3U1goLAOdsWxiSfgXalI2mGC7p3GkGZ8wIY2JbjHlkAsuhXpIQwBPYZriQ4Kx0ISP6EuIy1vyaoQp47vTvCS_v3-7v_3R3P1a_7y9uWu81KY0AkBaNJyPVnjTqq7ve6bRIyrQaJlA0XWm80y0HDvgTHBslbHGWOuNkeKSXB3vblP8s8Nc3Byyx2mCBeMuu8qorlO6gvII-hRzTji6bQozpL3jzB3cuoM4dxDnrHL_3Lp1rX043d_1Mw7n0klmzT-ecsgepjHB4kM-Y0IbJpmq2NcjhtXFU8Dksg-4eBxCqsLcEMP__3gGh42WiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77458856</pqid></control><display><type>article</type><title>Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ferraro, Pasquale ; Carrier, Michel ; White, Michel ; Pelletier, Guy B. ; Pelletier, L. Conrad</creator><creatorcontrib>Ferraro, Pasquale ; Carrier, Michel ; White, Michel ; Pelletier, Guy B. ; Pelletier, L. Conrad</creatorcontrib><description>The treatment of severe or persistent acute rejection remains difficult despite newer immunosuppressive agents available.
To evaluate the effectiveness of rabbit antithymocyte globulin and methotrexate as therapy for severe or persistent acute cardiac allograft rejection, we conducted a retrospective analysis of clinical and laboratory data from 150 consecutive heart transplant recipients between 1983 and 1994.
Thirteen episodes of severe or refractory acute rejection were treated with rabbit antithymocyte globulin in 10 patients. Rabbit antithymocyte globulin (125 mg/day for 3 consecutive days) was effective in 90% of patients. Therapy was well tolerated, and contributed to one infectious complication, no malignancy, and long-term survival in 8 of 10 patients. Recurrent rejection developed in 60% of patients. Methotrexate (7.5 to 15 mg/wk for 16 weeks) was administered to 8 patients with persistent rejection documented on three consecutive endomyocardial biopsies. Therapy was effective in 6 of the 8 patients, with one infectious complication and no malignancy on follow-up. White blood cell count decreased significantly during therapy (
p = 0.008). Seven of the 8 patients in the methotrexate group are long-term survivors.
Rabbit antithymocyte globulin is a valuable alternative in patients with severe or refractory acute rejection. Methotrexate is an important adjunct in patients with persistent rejection unresponsive to conventional immunosuppressive regimens.</description><identifier>ISSN: 0003-4975</identifier><identifier>EISSN: 1552-6259</identifier><identifier>DOI: 10.1016/0003-4975(95)00414-G</identifier><identifier>PMID: 7646098</identifier><identifier>CODEN: ATHSAK</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Antilymphocyte Serum - therapeutic use ; Azathioprine - therapeutic use ; Biological and medical sciences ; Cyclosporine - therapeutic use ; Evaluation Studies as Topic ; Female ; Graft Rejection - drug therapy ; Heart Transplantation ; Humans ; Immunomodulators ; Male ; Medical sciences ; Methotrexate - therapeutic use ; Middle Aged ; Pharmacology. Drug treatments ; Prednisone - therapeutic use ; Retrospective Studies ; Treatment Outcome</subject><ispartof>The Annals of thoracic surgery, 1995-08, Vol.60 (2), p.372-376</ispartof><rights>1995 The Society of Thoracic Surgeons</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-3aa49e711f93c7258bbb06ecee5a6e903e38878c0321e8a1031e25797799c7743</citedby><cites>FETCH-LOGICAL-c467t-3aa49e711f93c7258bbb06ecee5a6e903e38878c0321e8a1031e25797799c7743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0003-4975(95)00414-G$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3670405$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7646098$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ferraro, Pasquale</creatorcontrib><creatorcontrib>Carrier, Michel</creatorcontrib><creatorcontrib>White, Michel</creatorcontrib><creatorcontrib>Pelletier, Guy B.</creatorcontrib><creatorcontrib>Pelletier, L. Conrad</creatorcontrib><title>Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection</title><title>The Annals of thoracic surgery</title><addtitle>Ann Thorac Surg</addtitle><description>The treatment of severe or persistent acute rejection remains difficult despite newer immunosuppressive agents available.
To evaluate the effectiveness of rabbit antithymocyte globulin and methotrexate as therapy for severe or persistent acute cardiac allograft rejection, we conducted a retrospective analysis of clinical and laboratory data from 150 consecutive heart transplant recipients between 1983 and 1994.
Thirteen episodes of severe or refractory acute rejection were treated with rabbit antithymocyte globulin in 10 patients. Rabbit antithymocyte globulin (125 mg/day for 3 consecutive days) was effective in 90% of patients. Therapy was well tolerated, and contributed to one infectious complication, no malignancy, and long-term survival in 8 of 10 patients. Recurrent rejection developed in 60% of patients. Methotrexate (7.5 to 15 mg/wk for 16 weeks) was administered to 8 patients with persistent rejection documented on three consecutive endomyocardial biopsies. Therapy was effective in 6 of the 8 patients, with one infectious complication and no malignancy on follow-up. White blood cell count decreased significantly during therapy (
p = 0.008). Seven of the 8 patients in the methotrexate group are long-term survivors.
Rabbit antithymocyte globulin is a valuable alternative in patients with severe or refractory acute rejection. Methotrexate is an important adjunct in patients with persistent rejection unresponsive to conventional immunosuppressive regimens.</description><subject>Adult</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Azathioprine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cyclosporine - therapeutic use</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Graft Rejection - drug therapy</subject><subject>Heart Transplantation</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisone - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0003-4975</issn><issn>1552-6259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE2LFDEQhoMo67j6DxRykEUPvSadr85FWBYdhQUv6zlUp6t3snR3xiSzOP9-M84wR09F8T5vUTyEvOfsmjOuvzDGRCOtUZ-s-syY5LJZvyArrlTb6FbZl2R1Rl6TNzk_1rWt8QW5MFpqZrsV8TdLCWWzn6PfF6QPU-x3U1goLAOdsWxiSfgXalI2mGC7p3GkGZ8wIY2JbjHlkAsuhXpIQwBPYZriQ4Kx0ISP6EuIy1vyaoQp47vTvCS_v3-7v_3R3P1a_7y9uWu81KY0AkBaNJyPVnjTqq7ve6bRIyrQaJlA0XWm80y0HDvgTHBslbHGWOuNkeKSXB3vblP8s8Nc3Byyx2mCBeMuu8qorlO6gvII-hRzTji6bQozpL3jzB3cuoM4dxDnrHL_3Lp1rX043d_1Mw7n0klmzT-ecsgepjHB4kM-Y0IbJpmq2NcjhtXFU8Dksg-4eBxCqsLcEMP__3gGh42WiA</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>Ferraro, Pasquale</creator><creator>Carrier, Michel</creator><creator>White, Michel</creator><creator>Pelletier, Guy B.</creator><creator>Pelletier, L. Conrad</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection</title><author>Ferraro, Pasquale ; Carrier, Michel ; White, Michel ; Pelletier, Guy B. ; Pelletier, L. Conrad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-3aa49e711f93c7258bbb06ecee5a6e903e38878c0321e8a1031e25797799c7743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Azathioprine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cyclosporine - therapeutic use</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Graft Rejection - drug therapy</topic><topic>Heart Transplantation</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisone - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ferraro, Pasquale</creatorcontrib><creatorcontrib>Carrier, Michel</creatorcontrib><creatorcontrib>White, Michel</creatorcontrib><creatorcontrib>Pelletier, Guy B.</creatorcontrib><creatorcontrib>Pelletier, L. Conrad</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ferraro, Pasquale</au><au>Carrier, Michel</au><au>White, Michel</au><au>Pelletier, Guy B.</au><au>Pelletier, L. Conrad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection</atitle><jtitle>The Annals of thoracic surgery</jtitle><addtitle>Ann Thorac Surg</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>60</volume><issue>2</issue><spage>372</spage><epage>376</epage><pages>372-376</pages><issn>0003-4975</issn><eissn>1552-6259</eissn><coden>ATHSAK</coden><abstract>The treatment of severe or persistent acute rejection remains difficult despite newer immunosuppressive agents available.
To evaluate the effectiveness of rabbit antithymocyte globulin and methotrexate as therapy for severe or persistent acute cardiac allograft rejection, we conducted a retrospective analysis of clinical and laboratory data from 150 consecutive heart transplant recipients between 1983 and 1994.
Thirteen episodes of severe or refractory acute rejection were treated with rabbit antithymocyte globulin in 10 patients. Rabbit antithymocyte globulin (125 mg/day for 3 consecutive days) was effective in 90% of patients. Therapy was well tolerated, and contributed to one infectious complication, no malignancy, and long-term survival in 8 of 10 patients. Recurrent rejection developed in 60% of patients. Methotrexate (7.5 to 15 mg/wk for 16 weeks) was administered to 8 patients with persistent rejection documented on three consecutive endomyocardial biopsies. Therapy was effective in 6 of the 8 patients, with one infectious complication and no malignancy on follow-up. White blood cell count decreased significantly during therapy (
p = 0.008). Seven of the 8 patients in the methotrexate group are long-term survivors.
Rabbit antithymocyte globulin is a valuable alternative in patients with severe or refractory acute rejection. Methotrexate is an important adjunct in patients with persistent rejection unresponsive to conventional immunosuppressive regimens.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>7646098</pmid><doi>10.1016/0003-4975(95)00414-G</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4975 |
| ispartof | The Annals of thoracic surgery, 1995-08, Vol.60 (2), p.372-376 |
| issn | 0003-4975 1552-6259 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77458856 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Antilymphocyte Serum - therapeutic use Azathioprine - therapeutic use Biological and medical sciences Cyclosporine - therapeutic use Evaluation Studies as Topic Female Graft Rejection - drug therapy Heart Transplantation Humans Immunomodulators Male Medical sciences Methotrexate - therapeutic use Middle Aged Pharmacology. Drug treatments Prednisone - therapeutic use Retrospective Studies Treatment Outcome |
| title | Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A03%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antithymocyte%20globulin%20and%20methotrexate%20therapy%20of%20severe%20or%20persistent%20cardiac%20allograft%20rejection&rft.jtitle=The%20Annals%20of%20thoracic%20surgery&rft.au=Ferraro,%20Pasquale&rft.date=1995-08-01&rft.volume=60&rft.issue=2&rft.spage=372&rft.epage=376&rft.pages=372-376&rft.issn=0003-4975&rft.eissn=1552-6259&rft.coden=ATHSAK&rft_id=info:doi/10.1016/0003-4975(95)00414-G&rft_dat=%3Cproquest_cross%3E77458856%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77458856&rft_id=info:pmid/7646098&rft_els_id=000349759500414G&rfr_iscdi=true |